Evidence map›Paper›PMID 35967081›Full record

ArticleOpen research Europe2021

Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.

Mathieu Bléry, Manel Mrabet-Kraiem, Ariane Morel, Florence Lhospice, Delphine Bregeon, Cécile Bonnafous, Laurent Gauthier, Benjamin Rossi, Romain Remark, Stéphanie Cornen and 19 more

Open access · goldAbstract read
In one paragraph

Article in Open research Europe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer.International journal of molecular sciences · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 5 institutions in 3 countries.

Mathieu Bléry *Innate Pharma, Marseille, France.
Manel Mrabet-Kraiem *Innate Pharma, Marseille, France.
Ariane MorelInnate Pharma, Marseille, France.
Florence LhospiceInnate Pharma, Marseille, France.ORCID https://orcid.org/0000-0002-2868-1181
Delphine BregeonInnate Pharma, Marseille, France.
Cécile BonnafousInnate Pharma, Marseille, France.
Laurent GauthierInnate Pharma, Marseille, France.
Benjamin RossiInnate Pharma, Marseille, France.
Romain RemarkInnate Pharma, Marseille, France.
Stéphanie CornenInnate Pharma, Marseille, France.
Nadia AncerizInnate Pharma, Marseille, France.
Nicolas ViaudInnate Pharma, Marseille, France.
Sylvia TrichardInnate Pharma, Marseille, France.
Sabrina CarpentierInnate Pharma, Marseille, France.
Alix Joulin-GietInnate Pharma, Marseille, France.
Gwendoline GrondinInnate Pharma, Marseille, France.
Veronika LiptakovaInstitute for Molecular Medicine, Goethe-University Frankfurt am Main, Frankfurt am Main, Germany.
Younghoon KimInstitute for Molecular Medicine, Goethe-University Frankfurt am Main, Frankfurt am Main, Germany.
Laurent DanielAssistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Marseille, France.
Aurélie HaffnerAssistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Marseille, France.
Nicolas MacagnoAssistance Publique des Hôpitaux de Marseille, Hôpital de la Timone, Marseille, France.ORCID https://orcid.org/0000-0002-9882-2162
Laurent PouyetMI-mAbs, Aix Marseille University, Marseille, France.
Ivan PerrotInnate Pharma, Marseille, France.
Carine PaturelInnate Pharma, Marseille, France.
Yannis MorelInnate Pharma, Marseille, France.
Alexander SteinleInstitute for Molecular Medicine, Goethe-University Frankfurt am Main, Frankfurt am Main, Germany.ORCID https://orcid.org/0000-0001-5081-8503
François RomagnéMI-mAbs, Aix Marseille University, Marseille, France.
Emilie Narni-MancinelliAix Marseille University, CNRS, INSERM, CIML, Marseille, France.ORCID https://orcid.org/0000-0002-7001-1026
Eric VivierInnate Pharma, Marseille, France.ORCID https://orcid.org/0000-0001-7022-8287
Innate Pharma (France) · FRGoethe University Frankfurt · DEHôpital de la Timone · FRAix-Marseille Université · FRCentre National de la Recherche Scientifique · FR

Funding

European Research Council 694502European Research Council 875102
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADCcancer immunotherapyMICA

Identifiers

PMID35967081
PMCPMC7613279
OpenAlexW3200640217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.